The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study: Rationale, design and methods

Riccardo Calvani, Anna Picca, Federico Marini, Alessandra Biancolillo, Matteo Cesari, Vito Pesce, Angela Maria Serena Lezza, Maurizio Bossola, Christiaan Leeuwenburgh, Roberto Bernabei, Francesco Landi, Emanuele Marzetti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Sarcopenia, the progressive and generalised loss of muscle mass and strength/function, is a major health issue in older adults given its high prevalence and burdensome clinical implications. Over the years, this condition has been endorsed as a marker for discriminating biological from chronological age. However, the absence of a unified operational definition has hampered its full appreciation by healthcare providers, researchers and policy-makers. In addition to this unsolved debate, the complexity of musculoskeletal ageing represents a major challenge to the identification of clinically meaningful biomarkers. Here, we illustrate the advantages of biomarker discovery procedures in muscle ageing based on multivariate methodologies as an alternative approach to traditional single-marker strategies. The rationale, design and methods of the “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study are described as an application of a multi-marker strategy for the development of biomarkers for the newly operationalised Physical Frailty & Sarcopenia condition.

Original languageEnglish
Pages (from-to)19-25
JournalEuropean Journal of Internal Medicine
Volume56
DOIs
Publication statusPublished - 2018

Fingerprint

Sarcopenia
Biomarkers
Muscle Strength
Administrative Personnel
Health Personnel
Research Personnel
Muscles
Health

Keywords

  • Cytokine
  • Disability
  • Inflammation
  • Multivariate analysis
  • Muscle atrophy
  • Neuromuscular junction

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study : Rationale, design and methods. / Calvani, Riccardo; Picca, Anna; Marini, Federico; Biancolillo, Alessandra; Cesari, Matteo; Pesce, Vito; Lezza, Angela Maria Serena; Bossola, Maurizio; Leeuwenburgh, Christiaan; Bernabei, Roberto; Landi, Francesco; Marzetti, Emanuele.

In: European Journal of Internal Medicine, Vol. 56, 2018, p. 19-25.

Research output: Contribution to journalArticle

Calvani, R, Picca, A, Marini, F, Biancolillo, A, Cesari, M, Pesce, V, Lezza, AMS, Bossola, M, Leeuwenburgh, C, Bernabei, R, Landi, F & Marzetti, E 2018, 'The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study: Rationale, design and methods', European Journal of Internal Medicine, vol. 56, pp. 19-25. https://doi.org/10.1016/j.ejim.2018.05.001
Calvani, Riccardo ; Picca, Anna ; Marini, Federico ; Biancolillo, Alessandra ; Cesari, Matteo ; Pesce, Vito ; Lezza, Angela Maria Serena ; Bossola, Maurizio ; Leeuwenburgh, Christiaan ; Bernabei, Roberto ; Landi, Francesco ; Marzetti, Emanuele. / The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study : Rationale, design and methods. In: European Journal of Internal Medicine. 2018 ; Vol. 56. pp. 19-25.
@article{f6ea9b2ada0946328708cbd2a65e1e1a,
title = "The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study: Rationale, design and methods",
abstract = "Sarcopenia, the progressive and generalised loss of muscle mass and strength/function, is a major health issue in older adults given its high prevalence and burdensome clinical implications. Over the years, this condition has been endorsed as a marker for discriminating biological from chronological age. However, the absence of a unified operational definition has hampered its full appreciation by healthcare providers, researchers and policy-makers. In addition to this unsolved debate, the complexity of musculoskeletal ageing represents a major challenge to the identification of clinically meaningful biomarkers. Here, we illustrate the advantages of biomarker discovery procedures in muscle ageing based on multivariate methodologies as an alternative approach to traditional single-marker strategies. The rationale, design and methods of the “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study are described as an application of a multi-marker strategy for the development of biomarkers for the newly operationalised Physical Frailty & Sarcopenia condition.",
keywords = "Cytokine, Disability, Inflammation, Multivariate analysis, Muscle atrophy, Neuromuscular junction",
author = "Riccardo Calvani and Anna Picca and Federico Marini and Alessandra Biancolillo and Matteo Cesari and Vito Pesce and Lezza, {Angela Maria Serena} and Maurizio Bossola and Christiaan Leeuwenburgh and Roberto Bernabei and Francesco Landi and Emanuele Marzetti",
year = "2018",
doi = "10.1016/j.ejim.2018.05.001",
language = "English",
volume = "56",
pages = "19--25",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study

T2 - Rationale, design and methods

AU - Calvani, Riccardo

AU - Picca, Anna

AU - Marini, Federico

AU - Biancolillo, Alessandra

AU - Cesari, Matteo

AU - Pesce, Vito

AU - Lezza, Angela Maria Serena

AU - Bossola, Maurizio

AU - Leeuwenburgh, Christiaan

AU - Bernabei, Roberto

AU - Landi, Francesco

AU - Marzetti, Emanuele

PY - 2018

Y1 - 2018

N2 - Sarcopenia, the progressive and generalised loss of muscle mass and strength/function, is a major health issue in older adults given its high prevalence and burdensome clinical implications. Over the years, this condition has been endorsed as a marker for discriminating biological from chronological age. However, the absence of a unified operational definition has hampered its full appreciation by healthcare providers, researchers and policy-makers. In addition to this unsolved debate, the complexity of musculoskeletal ageing represents a major challenge to the identification of clinically meaningful biomarkers. Here, we illustrate the advantages of biomarker discovery procedures in muscle ageing based on multivariate methodologies as an alternative approach to traditional single-marker strategies. The rationale, design and methods of the “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study are described as an application of a multi-marker strategy for the development of biomarkers for the newly operationalised Physical Frailty & Sarcopenia condition.

AB - Sarcopenia, the progressive and generalised loss of muscle mass and strength/function, is a major health issue in older adults given its high prevalence and burdensome clinical implications. Over the years, this condition has been endorsed as a marker for discriminating biological from chronological age. However, the absence of a unified operational definition has hampered its full appreciation by healthcare providers, researchers and policy-makers. In addition to this unsolved debate, the complexity of musculoskeletal ageing represents a major challenge to the identification of clinically meaningful biomarkers. Here, we illustrate the advantages of biomarker discovery procedures in muscle ageing based on multivariate methodologies as an alternative approach to traditional single-marker strategies. The rationale, design and methods of the “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study are described as an application of a multi-marker strategy for the development of biomarkers for the newly operationalised Physical Frailty & Sarcopenia condition.

KW - Cytokine

KW - Disability

KW - Inflammation

KW - Multivariate analysis

KW - Muscle atrophy

KW - Neuromuscular junction

UR - http://www.scopus.com/inward/record.url?scp=85046629147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046629147&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2018.05.001

DO - 10.1016/j.ejim.2018.05.001

M3 - Article

AN - SCOPUS:85046629147

VL - 56

SP - 19

EP - 25

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

ER -